肝动脉插管化疗栓塞治疗中晚期肝癌及其并发症的防治  

Hepatic Arterial Infusion Chemotherapy and Embolization in the Treatment of Hepatocellular Carcinoma and Prevention of the Complications after Treatment

作　　者：张继广[1] 许崇恩[1] 孙启龙[1] 

机构地区：[1]山东医科大学附属医院

出　　处：《齐鲁肿瘤杂志》1996年第3期216-218,共3页

摘　　要：我们运用导管法治疗６５例中晚期肝癌，巨块型占６１．３％，结节型占２６．１％，弥漫型占２１．６％，患者肿瘤直径约３ｃｍ～１８ｃｍ不等。随访６－３３个月，多数患者治疗后肿瘤缩小，单纯灌注化疗组１２个月生存率为６．６％，化疗＋碘油＋明胶海绵生存率最高为３７．５％，最长的１例，生存３０个月。影响疗效的因素有：（１）肿瘤分期，（２）门静脉癌栓，（３）肝动脉治疗方法。并探讨治疗后并发症的产生原因和预防措施。patients with moderate and advanced stage of hepatocellular carcinoma were treated with hepatic arterial infusion chemotherapy and embolization.Among them,61.3% was of massive type,26.1% of nodular type and 13.8% of diffusd infiltrating type.the size of tumors were 3cm to 18cm.Mostofthe tumors decreased in size after the treatment.In 65 patients follow ups were six to thirty three months.The one year survival rate was 6.6%in the hepatic arterial infusion group and 37.5^ in the hepatic arterial infusion+hepatic arterial embolization (Iodizedoil+Gelfoam)group.The longest survival period was 30 months after initial hepatic arterial infusion and emboliization.Factors influencing theraputic effect were:(1)stage of tumor,(2)tumr or thrombus in the portal vein,(3)methods of hepatic infusion and hepatic arterial embolization.The cause of complication after the treament and the way of prevention were discussed in detail.

关 键 词：肝癌 并发症 肝动脉插管栓塞化疗 疗效 影响因素 

分 类 号：R735.7[医药卫生—肿瘤]